China NT Pharma Group Company Limited (NT Pharma) announced the appointment of Mr. Lou Yongbin, aged 46, as a Non-executive Director effective 13 April 2026.

Mr. Lou brings more than 20 years of entrepreneurial, management and investment experience, including prior leadership roles at Yiwu Junbin Ribbon Factory (2005-2012), Zhejiang Guihui Trading (2012-2016), Yiwu Panshi Real Estate (since 2022) and Zhejiang Kangyuan Medical Devices (chairman since June 2024).

Governance and tenure • Appointment term: three years, subject to retirement and re-election at the next annual general meeting • Remuneration: No director’s fee will be paid for his non-executive role • Board assessment: Nomination Committee confirms compliance with board-diversity policy and views Lou’s expertise as supportive of the Group’s integration of newly acquired medical-technology assets and its strategic shift toward an AI healthcare platform.

Shareholding structure • Mr. Lou directly owns 61.07 million shares, representing approximately 6.43 % of NT Pharma’s issued share capital. • His brother, Mr. Lou Yongjun, holds 47.33 million shares, or about 4.99 %. • No voting or acting-in-concert arrangement exists between the brothers beyond their familial relationship.

There are no additional matters requiring disclosure under Rule 13.51(2) of the Hong Kong Listing Rules. The Board extended a formal welcome to Mr. Lou upon confirmation of his appointment.